Our human iPSC-derived cardiomyocytes allow scientists to build their own human cellular models to accelerate their research. The use of iPSC-derived cardiomyocytes as an in vitro research model provides a major advantage over primary cells in that they provide a continuous source of cardiomyocytes from the same genetic background for use in multiple experiments. Our human cardiomyocytes derived from iPS cells are ideal for use in cardiotoxicity testing, drug screening, drug validation as well as metabolism studies and electrophysiology applications.
Once thawed, our cardiomyocytes will soon begin to spontaneously beat in vitro and are characterized by the expression of cardiac-specific markers, including cardiac troponin (see the data below). We also provide a fully-defined culture medium and coating reagents optimized for use with the cardiomyocytes for maximal recovery and viability for experiment assays.
Reliably reproduce test results.
Maintain pure cultures for long-term experiments.
No need to pre-plate.
Validated on Fibronectin, Vitronectin, and Matrigel substrates.
Human iPSC-derived ventricular cardiomyocytes
Cardiomyocyte culture media and reagents
Human iPSC-derived atrial cardiomyocytes (in development)
To register your interest in Axol Human iPSC-Derived Atrial Cardiomyocytes or for further information, please fill in the form below and we will be in touch.
Thank you! Your request has been received.
An error occurred! Please email us at email@example.com.
Axol Human iPSC-Derived Ventricular Cardiomyocytes were cultured in Cardiomyocyte Maintenance Medium prior to being fixed and stained for the markers Sarcomeric Alpha Actinin and Cardiac Troponin. The cells were counterstained using DAPI to allow visualization of nuclei.
In a study by Christian Zuppinger at the University of Bern, Axol ventricular cardiomyocytes were cultured for 10 days then fixed and stained for a number of markers. In the image to the right, the cardiomyocytes were stained for the sarcomeric marker myomesin, which labels the M-line of sarcomeres in all species and all actin. The cells were counterstained using DAPI to allow visualization of nuclei. The results demonstrate that there is good sarcomere differentiation in these cells and the majority of cells are positive for muscle proteins.
In a later study, the ventricular cardiomyocytes were cultured for two weeks during which they formed a closed carpet in 2D culture. The image on the left shows the expression of the beta-myosin heavy chain and all actin in the cardiomyocytes. The cells were also counterstained with DAPI to visualize the nuclei.
'This batch of cardiomyocytes has exceeded expectations.'
Christian Zuppinger, University of Bern. December 2015.
Many thanks to Christian Zuppinger for sharing both his expertise and the data he generated using Axol Human iPSC-Derived Ventricular Cardiomyocytes.
In the images below, ventricular cardiomyocytes were fixed after 10 days in culture and stained for the gap junction protein connexin-43 and all actin .
Connexin-43 was found to be expressed by all cells as shown in the representative images.
Signaling and stress response
In collaboration with Christian Zuppinger - University of Bern
Telethonin is a sarcomeric titin-binding protein that may also play a role in signaling and stress-response.
Ankyrin repeat domain 1 (ANKRD1) is a cytoskeleton linker protein that acts as a stress-sensor in cardiac muscle.
In this video you can see how Axol Human iPSC-Derived Ventricular Cardiomyocytes begin to spontaneously beat after just 7 days in culture following thawing!
Axol Human iPSC-Derived Ventricular Cardiomyocytes form spontaneously beating spheroids when seeded in hanging drops. A cardiosphere after 10 days in culture can be seen in this video. (Kindly provided by Christian Zuppinger, University of Bern)
Axol Human iPSC-Derived Ventricular Cardiomyocytes can be used in calcium imaging assays as shown in this video. The data were provided by Dr Frances Brook and Dr Yu-Fen Chang, Oxford University. The cardiomyocytes were plated and cultured for seven days in Axol Cardiomyocyte Maintenance Medium, and then replated on Fibronectin/Gelatin (0.5% / 0.1%) coated plates for final analysis.
Data provided by Dr J. Maynes University of Toronto
Axol Human iPSC-Derived Ventricular Cardiomyocytes were treated with doxorubicin (control, 500 nM, 100 nM and 50 nM).
There was a dose-dependent response at 13 h and 24 h post-treatment with doxorubicin. Arrhythmias and loss of beating amplitude were seen at lower doxorubicin concentration, whereas higher doxorubicin concentrations resulted in tachycardia and ultimately cell death.
Posters and application notes
In vitro assays and screening platforms for exploring ventricular and atrial phenotypes in iPSC-derived cardiomyocytes
Serum-free human iPSC-derived cardiomyocytes for in vitrotesting
Effects of transient hypoxia/ischemia on inducible human pluripotent stem cell-derived cardiomyocytes
A drug discovery platform for the identification of novel infarct sparing agents for treatment of ischemic heart diseases
Non-invasive impedance monitoring of contractility in Axol Human iPSC-Derived Cardiomyocytes.
by Dr Jason Gill, Durham University (UK)